Quinupristin-dalfopristin: An overview

Pharmacotherapy

Volumn 20, Issue 12, 2000, Pages 1469-1485

  Delgado, George ^a   Neuhauser, Melinda M ^a   Bearden, David T ^a   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DALFOPRISTIN PLUS QUINUPRISTIN;

ARTHRALGIA; BACTERIOSTASIS; DOSE CALCULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENTEROCOCCUS FAECALIS; ENZYME ACTIVITY; HUMAN; KIDNEY FUNCTION; MYALGIA; NONHUMAN; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; STRUCTURE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0033673271     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.19.1469.34858     Document Type: Review

References (120)

1. RP 59500: A proposed mechanism for its bactericidal activity
2. Inhibition of protein synthesis by streptogramins and related antibiotics
3. Mechanism of action of streptogramins and macrolides
4. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500
5. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma
6. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared with alternative ratios for in vitro testing
7. The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens
8. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci
9. A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France
10. The in-vitro activity of RP 59500 against gram-positive cocci
11. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates
12. In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci
13. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria
14. Comparative in-vitro activity of RP 59500
15. In vitro anti-staphylococcal activity and testing of RP 59500, a new streptogramin, by two methods
16. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci
17. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies
18. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination
19. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens
20. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci
21. Comparative in vitro and bactericidal activity of RP 59500 (quinupristin/dalfopristin), against multi-drug resistant E. faecium
22. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms
23. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
24. In vitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to > 512 mg/L of gentamicin
25. In vitro activity of an orally administered streptogramin (RPR 106,972) compared with quinupristin/dalfopristin and erythromycin
26. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients
27. Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes
28. Effect of medium upon the MIC values of Synercid (RP 59500) against Haemophilus influenzae
29. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas
30. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae
31. In vitro activity of RP 59500 against Mycoplasma
32. The in vitro activity of Synercid (RP 59500) and RP 106972 against Chlamydia spp., Mycoplasma spp. and Ureaplasma urealyticum
33. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species
34. In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species
35. In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp
36. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam
37. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro
38. Evaluation of the 'in vitro' activity of RP 59500 against anaerobic bacteria: A collaborative European study
39. Comparative in-vitro activities of quinupristin-dalfopristin against gram-positive bloodstream isolates
40. Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results
41. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin
42. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae
43. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms
44. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
45. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
46. In vitro activity of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against vancomycin-susceptible (VS) E. faecalis and vancomycin-susceptible or -resistant (VR) E. faecium (VSEF and VREF)
47. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations
48. In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci
49. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
50. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents
51. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
52. In vitro bactericidal antagonism of Synercid (SYN) and beta-lactam against methicillin-resistant Staphylococcus aureus (MRSA) does not predict treatment failure in experimental endocarditis (EE)
53. Synercid (SYN) alone or combined with cefepime (FEP) in the treatment (Rx) of experimental endocarditis (EE) due to methicillin-resistant Staphylococcus aureus (MRSA) resistant to macrolide-lincosamide-streptogramin B (MLSB-R)
54. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates
55. In vitro efficacy of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA)
56. Quinupristin-dalfopristin (Q-D) alone or in combination with rifampin (Rif) in vitro and in experimental endocarditis caused by Staphylococcus aureus harboring different phenotypes of resistance to quinupristin or dalfopristin
57. Plasmid-mediated coresistance to streptogramins and vancomycin in Enterococcus faecium HM1032
58. Post-antibiotic effect of the new streptogramin RP 59500
59. Post-antibiotic effects of RP 59500 with Staphylococcus aureus
60. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms
61. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods
62. Pharmacodynamic activities of RP 59500 in an animal infection model
63. Distribution of genes encoding resistance to macrolides, lincosamides, and streptograrnins among staphylococci
64. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria
65. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
66. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis
67. A variety of gram-positive bacteria carry mobile reef genes
68. Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics
69. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans
70. Disposition of the radiolabelled streptogramin RP 59500 in healthy male volunteers
71. RP 59500 pharmacokinetics after single dose administration in healthy volunteers
72. Protein binding and its significance in antibacterial therapy
73. Multiple-dose pharmacokinetics and safety of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy volunteers
74. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers
75. Open, comparative, study of the safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in obese and in non-obese male subjects
76. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in patients with severe chronic renal failure and in healthy volunteers
77. Open, comparative study of the pharmacokinetic and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy male and female volunteers
78. Open, comparative study of the pharmacokinetic and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy elderly volunteers and healthy young volunteers
79. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
80. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus
81. Intracellular survival of enteric bacteria in cultured human enterocytes
82. Survival of Staphylococcus aureus inside neutrophils contributes to infection
83. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages
84. Uptake of quinupristin/dalfopristin (Q/D) into polymorphonuclear leukocytes (PMNs) in normal volunteers
85. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium
86. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection
87. Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/RP 54476)
88. A phase I, open-label, single-dose study of blood and blister fluid pharmacokinetics of quinupristin/dalfopristin (Q/D, RP 59500, Synercid)
89. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis
90. Cerebrospinal fluid concentrations of quinupristin/dalfopristin
91. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid skin and skin structure infection group
92. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid emergency-use study group
93. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: Comparison with a control cohort
94. Efficacy of quinupristin/dalfopristin (Synercid, RP 59500) in the treatment of patients with positive blood cultures in global phase III studies
95. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia
96. Quinupristin/dalfopristin (Synercid) therapy of methicillin-resistant Staphylococcus aureus infections
97. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial pneumonia group
98. Randomized, double blind, comparative, multicenter study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia (CAP) [abstr]
99. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns
100. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinupristin/dalfopristin)
101. Vancomycin-resistant enterococci osteomyelitis in the foot. A case report
102. Treatment of vancomycin-resistant Enterococcus faecium infections
103. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): A report of fifteen cases
104. Quinupristin-dalfopristin
105. Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid) in the global development program
106. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines
107. Characteristics of arthralgias/myalgias associated with quinupristin/dalfopristin (Q/D, Synercid)
108. Cytochrome P-450 3A4 (CYP3A4) inhibition by quinupristin/dalfopristin (Q/D): Interaction with nifedipine (N) in normal volunteers
109. Effect of quinupristin/dalfopristin on FK-506 (tacrolimus) blood levels in liver transplanted recipients
110. Randomized, crossover, phase I study of the interaction between quinupristin/dalfopristin (Q/D, RP 59500, Synercid) at steady state and cyclosporine in healthy volunteers
111. Interaction between quinupristin/dalfopristin and cyclosporine
112. Gram-positive infections: Pharmacy issues and strategy for quinupristin/dalfopristin
113. Comparative In vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci
114. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains